• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email
    SC 13D/A 1 sc13da409076057_07312024.htm AMENDMENT NO. 4 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 4)1

    LifeVantage Corporation

    (Name of Issuer)

    Common Stock, par value $0.0001

    (Title of Class of Securities)

    53222K205

    (CUSIP Number)

    BRADLEY L. RADOFF

    2727 Kirby Drive

    Unit 29L

    Houston, Texas 77098

     

    RYAN NEBEL

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 29, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 53222K205

      1   NAME OF REPORTING PERSON  
             
            The Radoff Family Foundation  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            TEXAS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         82,500  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              82,500  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            82,500  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    2

    CUSIP No. 53222K205

      1   NAME OF REPORTING PERSON  
             
            Bradley L. Radoff  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF, AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         634,000  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              634,000  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            634,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.99%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    3

    CUSIP No. 53222K205

     

    The following constitutes Amendment No. 4 to the Schedule 13D filed by the undersigned (“Amendment No. 4”). This Amendment No. 4 amends the Schedule 13D as specifically set forth herein.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    The Shares purchased by the Radoff Foundation were purchased with working capital. The aggregate purchase price of the 82,500 Shares directly owned by the Radoff Foundation is approximately $417,710, including brokerage commissions.

    The Shares directly owned by Mr. Radoff were purchased with personal funds. The aggregate purchase price of the 551,500 Shares directly owned by Mr. Radoff is approximately $2,096,633, including brokerage commissions.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) – (c) and (e) are hereby amended and restated to read as follows:

    The aggregate percentage of Shares reported owned by each person named herein is based upon 12,700,556 Shares outstanding as of May 1, 2024, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 2, 2024.

    A.The Radoff Foundation
    (a)As of the date hereof, the Radoff Foundation beneficially owns directly 82,500 Shares.

    Percentage: Less than 1%

    (b)1. Sole power to vote or direct vote: 82,500
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 82,500
    4. Shared power to dispose or direct the disposition: 0

      

    B.Mr. Radoff
    (a)As of the date hereof, Mr. Radoff beneficially owns directly 551,500 Shares. As a director of the Radoff Foundation, Mr. Radoff may be deemed to beneficially own the 82,500 Shares owned by the Radoff Foundation.

    Percentage: Approximately 4.99%

    (b)1. Sole power to vote or direct vote: 634,000
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 634,000
    4. Shared power to dispose or direct the disposition: 0

    4

    CUSIP No. 53222K205

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each Reporting Person disclaims beneficial ownership of the Shares that he or it does not directly own.

    (c)       Schedule B annexed hereto lists all transactions in securities of the Issuer by the Reporting Persons during the past 60 days. All of such transactions were effected in the open market unless otherwise noted therein.

    (e)       As of July 31, 2024, the Reporting Persons ceased to be the beneficial owners of more than 5% of the Shares of the Issuer.

     

    5

    CUSIP No. 53222K205

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: July 31, 2024

      The Radoff Family Foundation
       
      By:

    /s/ Bradley L. Radoff

        Name: Bradley L. Radoff
        Title: Director

     

     

     

    /s/ Bradley L. Radoff

      Bradley L. Radoff

    6

    CUSIP No. 53222K205

     

    SCHEDULE B

    Transactions in the Securities of the Issuer During the Past Sixty (60) Days

    Nature of the Transaction

    Amount of Securities

    Purchased/(Sold)

    Price ($)

    Date of

    Purchase/Sale

     

    THE RADOFF FAMILY FOUNDATION

     

    Purchase of Common Stock 1,000 6.3609 07/03/2024
    Purchase of Common Stock 2,500 5.7789 07/08/2024
    Purchase of Common Stock 5,000 5.5694 07/09/2024
    Purchase of Common Stock 2,500 6.3358 07/15/2024

     

    BRADLEY L. RADOFF

     

    Sale of Common Stock (1,000)  7.9990 06/03/2024
    Purchase of Common Stock 11,950  6.4091 06/24/2024
    Purchase of Common Stock 5,000  6.3080 07/01/2024
    Purchase of Common Stock 4,000  6.2218 07/05/2024
    Purchase of Common Stock 6,000  5.8864 07/08/2024
    Purchase of Common Stock 10,000  5.6157 07/09/2024
    Purchase of Common Stock 1,000  6.1673 07/11/2024
    Purchase of Common Stock 4,000  6.4034 07/16/2024
    Purchase of Common Stock 7,500  6.4153 07/18/2024
    Purchase of Common Stock 2,500  6.7236 07/22/2024
    Sale of Common Stock (148,000)  8.3214 07/29/2024
    Sale of Common Stock (8,600)  8.4577 07/30/2024
    Sale of Common Stock (32,000)  7.9561 07/31/2024

     

     

     

    Get the next $LFVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      6/17/25 4:11:27 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      12/17/24 5:00:17 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care